Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Femara
Letrozole is an oral nonsteroidal aromatase inhibitor primarily used to treat hormone receptor-positive breast cancer in postmenopausal women. It works by blocking the enzyme aromatase, which converts androgens to estrogens in peripheral tissues. By reducing estrogen levels, letrozole inhibits the growth of estrogen-dependent breast cancer cells.
Treatment of hormone receptor-positive breast cancer in postmenopausal women.
Outcome:
Significantly increased letrozole levels
Mechanism:
Potent inhibition of CYP3A4
Outcome:
Increased letrozole levels
Mechanism:
Inhibition of CYP2A6 and CYP3A4
Outcome:
Reduced efficacy of letrozole
Mechanism:
Competition for estrogen receptor binding
Most likely new formulation: Extended-release formulation for improved patient compliance (Year: 2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood of letrozole remaining a standard treatment option for hormone receptor-positive breast cancer in the next 5 years.
Antineoplastic, Aromatase Inhibitor
Nonsteroidal aromatase inhibitor